R&D
AbCellera and Vertex Partner on Next-Gen T-Cell Engagers for Autoimmune Disease
Vertex pays $28 million upfront and will fund all R&D for multispecific antibodies AbCellera discovers, pushing T-cell engagers beyond cancer into autoimmunity.